Browse the evidence

Weight loss interventions in women with breast cancer significantly reduced body weight and fat mass but also reduced lean mass.

Practitioners should be aware that while weight loss interventions can be effective, they may also lead to reductions in lean mass.

Obesity is a leading risk factor for cardiovascular disease (CVD).

Clinicians should prioritize addressing obesity to mitigate CVD risks.

Obesity contributes to the emergence of cardiovascular risk factors such as dyslipidaemia, type 2 diabetes, hypertension, and sleep disorders.

Addressing obesity may help in managing these associated cardiovascular risk factors.

Semaglutide and tirzepatide show therapeutic potential as cardioprotective and nephroprotective agents.

Practitioners can consider semaglutide and tirzepatide for patients at risk of cardiovascular and renal diseases.

The GLP-1RA/GIPR antagonist MariTide achieved substantial reductions in weight and HbA1c.

MariTide may be an effective option for weight management and glycemic control in patients.

Current pharmacotherapy options for obesity include agents like liraglutide, semaglutide, and tirzepatide.

Practitioners should be aware of these specific pharmacotherapy options for treating obesity.

Novel therapies, including dual and triple incretin agonists, are under investigation for obesity treatment.

Practitioners should stay informed about emerging therapies that may enhance obesity treatment.

Bariatric surgery before liver transplantation is feasible and can improve liver function for patients on the transplant waiting list.

Bariatric surgery may be a beneficial option for patients with obesity awaiting liver transplantation to enhance liver function.

The consensus defines sarcopenic obesity with a 3-step algorithm, including screening, diagnosis, and intervention.

Practitioners can use this algorithm for diagnosing and managing sarcopenic obesity.

Multidomain lifestyle intervention may slow biological aging long term, as captured by an FI-E.

Practitioners may consider recommending multidomain lifestyle interventions to promote long-term health benefits.

FI-E scores were relatively lower among lifestyle participants throughout follow-up.

Lifestyle interventions may be effective in reducing frailty over time.

Male participants experienced greater effects than females (P < 0.001).

Practitioners should consider gender differences when designing resistance training programs.

Tirzepatide was evaluated for its effects on cardiovascular and diabetic kidney disease biomarkers in overweight and obese adults with type 1 diabetes over a period of 21 months.

Practitioners may consider tirzepatide for managing cardiovascular and kidney health in overweight and obese patients with type 1 diabetes.

Strength gains are stimulated through a sequence of events including maximal mental effort and neural activation.

Emphasize mental effort and neural activation in training programs to enhance strength gains.

Once semaglutide is stopped, people regain most of their pretreatment weight.

Practitioners should inform patients about the potential for weight regain after stopping treatment.

Dietary intake of trans fatty acids, palmitic acid, stearic acid, and saturated fatty acids from meat and unprocessed meat was modestly associated with a higher risk of coronary events.

Reducing intake of certain fatty acids may be beneficial for lowering coronary event risk.

Bariatric surgery resulted in an overall 25.8% weight reduction, outperforming lifestyle and pharmacotherapy interventions.

Bariatric surgery may be the most effective intervention for significant weight loss in obese individuals.

GLP-1 receptor agonists and dual receptor agonists effectively counteract hyperglycemia and obesity.

These medications may be prioritized in treatment plans for T2D patients with obesity.

Unimolecular GLP-1/GCG dual agonist and GLP-1/GIP/GCG triple agonist may offer superior weight loss efficacy over GLP-1 agonist.

Practitioners should consider these new agonists for potentially better weight loss outcomes.

Food is Medicine (FIM) interventions link food security, nutrition security, health, and health equity integrated into health care delivery.

Practitioners should consider integrating FIM interventions into health care to address food and nutrition security.

Recent patents emphasize the development of GLP-1 receptor agonists (GLP-1RAs) for oral delivery and improved weight reduction effects.

Practitioners should consider the potential of new GLP-1RAs that are orally administered and may enhance weight loss.

GLP-1 receptor agonists demonstrated a mean systolic BP reduction of -3.37 mmHg and a mean diastolic BP reduction of -1.05 mmHg compared with placebo.

GLP-1 receptor agonists can be considered for managing blood pressure in overweight or obese patients.

The BP reduction effect of GLP-1 RAs was consistent across subgroups for diabetic status, formulation, follow-up duration, and route of administration.

GLP-1 receptor agonists can be effectively used across different patient subgroups for BP management.

Low intracellular ATP levels lead to carbohydrate-dependent hunger and impaired satiety.

Recognizing the link between ATP levels and hunger can aid in obesity treatment strategies.